Product Pipeline
Manufacturing Platforms
Services & Support
Human Resources & Careers

Company Profile

Shanghai IxCell Biotech Co★→✔¥., Ltd. is a biophar<♥maceutical company spε↔ecializing in the developm♦'☆¶ent and industrial prod ≈©©uction of cell-based drugs. With a fΩαλocus on cellular therapeutic←≤→≈s, we are dedicated to del©☆>ivering high-quality, innovative p→☆ λroducts. Our core portfolio spans thre®₽§e key areas: mesenchymal st←β₩≥em cell drugs, induced pluripotent ≠•$stem cell drugs, and im¶•§mune cell drugs. These products ar↔×σe supported by a state-o♥$f-the-art cell manufacturing platformφ" designed to meet the highest p←£roduction standards.
Driven by independent research☆✘® and a commitment to innovation, we ←±✔₽have secured over 40 patents relaδ'↑ ted to cell therapy and h♥$™ave set industry-leading standards in₩≤¥ manufacturing. Our mesenchymal stem c★♠βell drug for the treatment of knee o↑∞ steoarthritis is among the first in Ω←China to reach Phase III ∑↑☆ clinical trials, positionin₽£♥§g it to become one of the c₽γ‍≈ountry’s earliest commercialize★§≥d stem cell therapies.
We operate a 4,000m² GMP-complian←™≤₽t production facility locat∏£ed in the heart of Zh↑"angjiang Hi-Tech Park in Pudong, Sh♠¶>anghai. This facility integrat∑₽₽ es both research and manufacturing, ¥↓₩↕enabling us to advanc$✘e our mission of bringing cutting-e‌​dge cell therapies to market. The compa♣∑<✔ny has been recognize βd with several honorγ©&s, including High-Tech Enterprise, Shan× ghai Specialized and New Small Enterpr÷<£ ise, and Shanghai Key Enterprise >€status.

  • 00+Years

    Industry-Specific Experience

  • 0000㎡

    Cellular Manufacturi₩≥ng Facility

  • 00%

    Skilled Technical Staff

  • 00+ 

    Patent Portfolio

  • Corporate Mission

    Dedicated to advancing exce$§₩∞llence in cell-based pharmaceu∏₹¥✔ticals.

  • Corporate Vision

    To be a leading pionγ✘σ>eer in the cellular drug manu©>↓εfacturing industry.

  • Core Values

    Integrity · Responsibility ·$γ<λ Leadership

    Integrity :We believe in open, honest commun ¥ication. Every member of our t±↑"eam is encouraged to speak with c♣↕omplete transparency, sharing their th♦™♠εoughts and insights fully an​≠→∑d truthfully. Equally important is Ω"→the role of the listener, who shouldλ→ engage with genuine↑≠≤ attention and respect, fostering a cu÷♦♦lture of mutual trust and underst>≠anding.

    Responsibility :We are committed to facing chall<∑enges with integrity and courage. ↑↑λWe do not tolerate deceit, avoidanc∑∑×σe, or the neglect of issues. Instead'★, we address problems hea↓₽φd-on, resolve them with diligence, and‍≠ embrace difficulties as opportunitiesβ'& for growth. Every individual takesδ  ✘ full accountability for their &↕ε♠actions, ensuring that responsibility ∞•✔✔is never shifted or deferred.

    Leadership :True leadership is built on ini♥↔•↔tiative and the ability to lea¶αd by example. We value in★∞dividuals who show competence and de"∏♣cisiveness in their wor‌¥k, and who are able to guide others wit★♥$h clarity and inspiration. As lead>↓ers, we aim to teach through both ×λ<words and actions, cr∞£eating a supportive environm‌±γ<ent where teams can thrive ©™and succeed together.

Core Team

Our core team is composed of highly​← accomplished indivi‍↕duals from world-renowneφ↓←d institutions such as Ha®<₽rvard University and Yale University, a₩π✘s well as leading internation≥☆al companies in the cell pharmaceutic ↑•al industry. They bring extensive e♠​  xpertise across the εΩentire spectrum of cell♥↑ therapy, including mesenchymal stem↑​" cells, induced pluripotent stem γ≤cells, and immune cells. Our team's comλ∑≠prehensive experience©♣λ spans basic scientific research,Ω€§☆ process development, large-scale ph✘δ≥armaceutical manufacturing, and ≈₩α÷navigating the complexit•♠ies of drug commerci ♣alization. This diverse and in-depth →≥♥knowledge positions us to l  $δead advancements in the field of cellul≈¥ar medicine.

With a steadfast commitme♥♥nt to excellence, we conti‍¶λnuously strive to elevate the stεεandards of cell-based pharmaceuticalΩ↑₹s, ensuring that every s Ω☆tep forward is grounded in ±← ↓diligence and precision.

  • 2023

    ·Launched Phase I Clinical Trial for Mes↓ε> enchymal Stem Cell Therapy for S™÷δtroke

    ·Completed Phase II Clinical Trial for M₽↕✘esenchymal Stem Cell Thera σ&±py for Knee Osteoarthritis ★★

    ·Launched Phase III Clinical Tr‍×ial for Mesenchymal Stem Cell Thera•✔σ₹py for Knee Osteoarthritis

    ·Advanced iPSC and Immune Ce®∏ εll Therapy Pipelines≈ε

    ·Recognized as a Specialized, Inn§♣ ovative Small and Medium-siz>α÷ed Enterprise in Shaα"δ nghai

  • 2022

    ·Completed Clinical Ph♥₹±​ase II Enrollment for Mese₹±✘αnchymal Stem Cell Therapy for K↔↔♣↑nee Osteoarthritis

    ·Received Clinical Trial Appr€"₩ovals from NMPA (National M₩≥×∑edical Products Administrat↕α₽↑ion) for Stroke and P↕✘↕"ulmonary Fibrosis Therapies

    ·Finalized Data Collection and Analy <₹sis for Phase II Knee Osteoarthritiδ ₹s Therapy

  • 2021

    ·Completed Phase I Clinical Project for ≠☆Mesenchymal Stem Cell Dr✔≈β✘ugs Targeting Knee O<✔steoarthritis

    ·Completed constructio‌α →n on 4000 m2 GMP laboratory located i₹§↔n the core area of Zhangjiang Hi-Tech Pβ$♦ark in Pudong, Shanghai.

  • 2020

    ·Passed National High-Tech Enterp♣≠rise Re-certification

  • 2019

    ·Received NMPA Approv•δ¥al for Mesenchymal Stem Cell Therapy f∏¶↑or Knee Osteoarthritis Clini↕£ ★cal Trial (National Medical Pr​✘oducts Administration)

    ·Accredited as the "iPSC Cl≈$inical Transformation Technology Pl♣™atform" by the Shang♣☆hai Science and Technology Comm₩↑ission

    ·Launched Phase I Clinical ∞↔Trial for Mesenchymal Stem Cell<β±$ Therapy for Knee Osteoarthr✔Ω×itis

  • 2018

    ·Submitted Investigational§¥ New Drug (IND) Application for £ Mesenchymal Stem Cell Therapy in Knee Oλ✔≈★steoarthritis

  • 2017

    ·Contributed to the Revision of the &★×↔quot;Technical Guidelines✔↓ for Cell Therapy Products"

    ·Designated as a National ÷≥High-tech Enterprise for t₹δhe first time

  • 2016

    ·Developed First Cell Therapy P¥φipeline for Knee Osteoart∑π≤§hritis

  • 2015

    ·Incubated iPSC Technology, Secu↔∏red Multiple National Grants

  • 2013

    ·Shanghai IxCell Biotech Co., Ltd. Estab≈♣lished in Zhangjiang Hi-Tech Park, Sh ≥anghai

Qualifications and Honors

Shanghai Sci-Tech Innovation E∞₹☆∏nterprise Listing Trai&®‌Ωning Database

Certified "Shanghai Induced Pεσ♠ luripotent Stem Cell Clinical Tr♦≤≤÷ansformation Profession₩♣♣↕al Technology Platfo♦↑≈rm" by the Shanghai Science an↔≈d Technology Commission

Joint Laboratory for Cell Quality F♦•©™unction Testing in collaboration wi®≠th the Shanghai Institute ↑βof Biomedical Technology

Shanghai Specialized, Innov★γative, and Unique Small and Medium-✔>±​sized Enterprise


National High-tech Enter₩&prise